Rajesh Devraj

Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.

Tansna Therapeutics, Inc. develops and offers oral drugs to treat epilepsy. It focuses on novel therapies for the treatment of central nervous system disorders. The company was founded by Max Baker in 2010 and is headquartered in St. Louis, MO.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Jubilant Biosys Ltd. specializes in drug discovery services, proprietary in-house innovation, and strategic investments. Its services include discovery informatics, computational chemistry, structural biology, chemistry, in vitro and in vivo biology, and toxicology. The company was founded by VN Balaji in 2001 and is headquartered in Noida, India.

Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.